Rozerem: profile and news

UPDATE 1-Takeda year profit up 9.8 pct, forecast flat  May 10, 2006
Actos diabetes drug and domestic sales of its Blopress hypertension treatment offset hefty marketing costs for its new sleeping pill Rozerem, launched in the ... - Reuters

Takeda Pharmaceutical's Full-Year Net Income Rises 13%  May 10, 2006
The company started sales there in September last year for Rozerem, a sleeping aid that is the first original formula Takeda has introduced in the US in six ... - Bloomberg

Takeda Says Outlook Regarding US TAP Buyout Is `Improving'  May 11, 2006
In September, Takeda started selling its Rozerem insomnia drug in the US using its own marketing employees, not TAP's sales staff. ... - Bloomberg

Takeda 05/06 profit up, plans share buybacks  May 11, 2006
Estimates. (R&D) spending and marketing costs for its new sleeping pill Rozerem, launched in the United States last September. Net ... - Reuters

Japan drug makers to face tough year on price cuts  May 9, 2006
...of its Actos diabetes drug abroad and its Blopress hypertension treatment in Japan offset hefty marketing costs for its new sleeping pill Rozerem, launched in ... - Reuters

Op-Ed Contributor Generic Smear Campaign  May 10, 2006
Lunesta (the one with the butterfly commercials), Sanofi-Aventis's Ambien CR (a controlled-release version of Ambien) and Takeda Pharmaceuticals' Rozerem. ... - New York Times,

Pfizer tries not to be caught napping  May 4, 2006
Another competitor, Rozerem from the Japanese company Takeda Pharmaceutical, is the world's first non-addictive sleeping pill. Rozerem ... - CNNMoney.com

The Quest for Rest  May 2, 2006
Although the current generation of drugs—products such as Ambien, Lunesta and Rozerem—don't have the addictive potential of the older sleep medications ... - Standard-Speaker,

Sepracor Shares Have Room For Downside  Apr 26, 2006
...companies in the space include King Pharmaceuticals (nyse: KG - news - people ), which markets Sonata, and Japan's Takeda Pharmaceutical, which markets Rozerem ... - Forbes

An industry in flux  Apr 21, 2006
...advertising. The agency won three DTC assignments in 2005, including Takeda Pharmaceutical North America Inc.’s insomnia drug Rozerem. ... - Med Ad News (subscription),